Press Releases
A Strategic Roadmap for Sustainable Growth - Samsung Biologics at J.P. Morgan Healthcare Conference 2022
At the 40th Annual J.P. Morgan Healthcare Conference, which was held virtually from January 10th to 13th, Samsung Biologics’ CEO John Rim shared the company’s sustainable growth plan, consolidating its vision and business goals for 2022.
During the main track presentation, which Samsung Biologics was invited to in 6 consecutive years, Rim addressed the three core pillars for the company’s multidimensional growth plan, encompassing expanded manufacturing capacity, continued advancements in business portfolio, and greater global footprint.
With the company aims to evolve as the top biopharmaceutical company, Rim outlined the key growth drivers for 2022 and here are some of the key highlights from the presentation.
Key achievements of 2021
Key achievements of 2021
Achievements of 2021
- Accumulated a total of 61 CMO contracts(As of thira quarter of 2021)
- Launched CDO process platform, S-CellerateTM (Offering expedited process for the development and commercialization of monoclonal antibodies)
- Marked record-high financial results(Accumulative revenue of KRW 1.24 trillion and operating profit of KRW 408.5 billion as of third quarter of 2021)
- Expanded mRNA services offerings(Signing mRNA DP contract, adding mRNA DS manufacturing suite, and securing additional land for the building of MMP)
- Launched ESG management system(lssuing first annual sustainability report, joining DOW jonse Sustainability World index(DJSI), participating in Sustainable Markets Initiative Task Force)
*Multi-Modal Plant
*Korea Corporate Governance Service
*Dow Jones Sustainability ‘World’ Index
*Sustainable Market Initiative
Business goals and vision for 2022
1) Expanded manufacturing capacity
Expanded manufacturing capacity
- Plant 1(30,000L)
- Plant 2(154,000L)
- Plant 3(180,000L)
- Plant 4(256,000L)
● Plant 4 partially operational (Q4 2022)
● Secure additional sites within Songdo for Bio Campus II
2) Advancements in business portfolio
Advancements in business portfolio
mAb/Fusion Protein
Cell/Gene Therapy Vaccine, Viral Vector
mRNA
mAb/Fusion Protein
+
Open Innovation
● Successfully process mRNA DS CGMP Ready (Q2 2022)
● Groundbreaking of Plant 5, which will offer multi-modal products including cell & gene therapies
and next-gen vaccines utilizing mRNA, pDNA and viral vectors, all at a single site
● Establish plans for Open Innovation Center
3) Greater global footprint
● Expand overseas, additionally to San Francisco R&D Center
Related contents
News Brief JP Morgan Healthcare Conference (Audio Link)
YouTube The Future of BioPharma: Plant 4
ESG Sustainability Report 2021
At the 40th Annual J.P. Morgan Healthcare Conference, which was held virtually from January 10th to 13th, Samsung Biologics’ CEO John Rim shared the company’s sustainable growth plan, consolidating its vision and business goals for 2022.
During the main track presentation, which Samsung Biologics was invited to in 6 consecutive years, Rim addressed the three core pillars for the company’s multidimensional growth plan, encompassing expanded manufacturing capacity, continued advancements in business portfolio, and greater global footprint.
With the company aims to evolve as the top biopharmaceutical company, Rim outlined the key growth drivers for 2022 and here are some of the key highlights from the presentation.
Key achievements of 2021
Key achievements of 2021
Achievements of 2021
- Accumulated a total of 61 CMO contracts(As of thira quarter of 2021)
- Launched CDO process platform, S-CellerateTM (Offering expedited process for the development and commercialization of monoclonal antibodies)
- Marked record-high financial results(Accumulative revenue of KRW 1.24 trillion and operating profit of KRW 408.5 billion as of third quarter of 2021)
- Expanded mRNA services offerings(Signing mRNA DP contract, adding mRNA DS manufacturing suite, and securing additional land for the building of MMP)
- Launched ESG management system(lssuing first annual sustainability report, joining DOW jonse Sustainability World index(DJSI), participating in Sustainable Markets Initiative Task Force)
*Multi-Modal Plant
*Korea Corporate Governance Service
*Dow Jones Sustainability ‘World’ Index
*Sustainable Market Initiative
Business goals and vision for 2022
1) Expanded manufacturing capacity
Expanded manufacturing capacity
- Plant 1(30,000L)
- Plant 2(154,000L)
- Plant 3(180,000L)
- Plant 4(256,000L)
● Plant 4 partially operational (Q4 2022)
● Secure additional sites within Songdo for Bio Campus II
2) Advancements in business portfolio
Advancements in business portfolio
mAb/Fusion Protein
Cell/Gene Therapy Vaccine, Viral Vector
mRNA
mAb/Fusion Protein
+
Open Innovation
● Successfully process mRNA DS CGMP Ready (Q2 2022)
● Groundbreaking of Plant 5, which will offer multi-modal products including cell & gene therapies
and next-gen vaccines utilizing mRNA, pDNA and viral vectors, all at a single site
● Establish plans for Open Innovation Center
3) Greater global footprint
● Expand overseas, additionally to San Francisco R&D Center
Related contents
News Brief JP Morgan Healthcare Conference (Audio Link)
YouTube The Future of BioPharma: Plant 4
ESG Sustainability Report 2021